The cardioprotective potential of soluble urokinase Plasminogen Activator Receptor (suPAR) in myocardial ischemia.

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Mr Thomas Pirker

Christchurch (New Zealand)

4 More presentations in this session

Presentation thumbnail

Sphingosine-1-phosphate reduces arterial thrombosis via enhanced endothelial thrombomodulin expression by S1PR1 signaling

Doctor M. Benkhoff (Duesseldorf, DE)

Abstract Slides Video

Presentation thumbnail

Single-cell mass cytometry analysis unveils prothrombotic expression and heterogeneity in essential thrombocythemia

Doctor S. Kuehne (Augsburg, DE)

Abstract Slides Video

Presentation thumbnail

Thrombin generation, fibrin clot permeation and lysis in patients with severe mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair: mitral fibrin study.

Doctor A. Siniarski (Krakow, PL)

Abstract Slides Video

Presentation thumbnail

Direct IL-6 inhibition prevents arterial thrombosis by reducing collagen-mediated platelets activation

Doctor S. Ministrini (Zurich, CH)

Abstract Slides Video

Access the full session

Session thumbnail

Platelets and thrombosis: novel experimental aspects

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

Soluble urokinase-type plasminogen activator surface receptor is associated with kidney disease in heart failure patients

Congress Presentation

Malonate protection against acute infarction in isolated mouse hearts is lost in the presence of insulin

Congress Presentation

Soluble urokinase plasminogen activator surface receptor as a prognostic biomarker in heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources